Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 2/2013

01-02-2013 | Original Paper

Prognostic value of ERCC1 in head and neck carcinoma treated with definitive or adjuvant radiotherapy

Authors: Vesna Bišof, Antonija Jakovčević, Sven Seiwerth, Zoran Rakušić, Slavko Gašparov

Published in: Journal of Cancer Research and Clinical Oncology | Issue 2/2013

Login to get access

Abstract

Purpose

To evaluate the prognostic significance of excision repair cross-complementation group 1 (ERCC1) expression in head and neck carcinoma patients treated with definitive radiotherapy (DR) or adjuvant radiotherapy (AR).

Methods

ERCC1 expression was assessed by immunohistochemical staining. A total of 48 patients were assessed.

Results

High ERCC1 expression was found in 23 patients (48 %). More ERCC1-positive tumours were detected in patients treated with DR than in patients treated with AR (73 vs. 36 %, respectively, p = 0.03). ERCC1 expression had no impact on overall survival neither in the whole cohort of patients (p = 0.16) nor in each particular treatment group (AR p = 0.98; DR p = 0.21).

Conclusions

ERCC1 expression had no predictive value in head and neck carcinoma patients treated with DR or AR. There might be difference in ERCC1 positivity that comes out of whether the assessment is done on biopsy or surgical specimens.
Literature
go back to reference Ahmad A, Robinson AR, Duensing A, van Drunen E, Berna Beverloo H, Weisberg H, Hasty P, Hoeijmakers JHJ, Niedernhofer LJ (2008) ERCC1-XPF endonuclease facilitates DNA double-strand break repair. Mol Cell Biol 28:5082–5092PubMedCrossRef Ahmad A, Robinson AR, Duensing A, van Drunen E, Berna Beverloo H, Weisberg H, Hasty P, Hoeijmakers JHJ, Niedernhofer LJ (2008) ERCC1-XPF endonuclease facilitates DNA double-strand break repair. Mol Cell Biol 28:5082–5092PubMedCrossRef
go back to reference Bergstralh DT, Sekelsky J (2008) Interstrand crosslink repair: can XPF-ERCC1 be let off the hook? Trends Genet 24:70–76PubMedCrossRef Bergstralh DT, Sekelsky J (2008) Interstrand crosslink repair: can XPF-ERCC1 be let off the hook? Trends Genet 24:70–76PubMedCrossRef
go back to reference Carles J, Monzo M, Amat M, Jansa S, Artells R, Navarro A, Foro P, Alameda F, Gayete A, Gel B, Miguel M, Albanell J, Fabregat X (2006) Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with stage I to II head and neck cancer. Int J Radiat Oncol Biol Phys 66:1022–1030PubMedCrossRef Carles J, Monzo M, Amat M, Jansa S, Artells R, Navarro A, Foro P, Alameda F, Gayete A, Gel B, Miguel M, Albanell J, Fabregat X (2006) Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with stage I to II head and neck cancer. Int J Radiat Oncol Biol Phys 66:1022–1030PubMedCrossRef
go back to reference De Castro G, Jr Pasini FS, Siqueira SA, Ferraz AR, Villar RC, Snitcovsky IM, Federico MH (2011) ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation. Oncol Rep 25:693–699PubMed De Castro G, Jr Pasini FS, Siqueira SA, Ferraz AR, Villar RC, Snitcovsky IM, Federico MH (2011) ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation. Oncol Rep 25:693–699PubMed
go back to reference De Silva IU, McHugh PJ, Clingen PH, Hartley JA (2000) Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol 20:7980–7990PubMedCrossRef De Silva IU, McHugh PJ, Clingen PH, Hartley JA (2000) Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol 20:7980–7990PubMedCrossRef
go back to reference Doll CM, Prystajecky M, Eliasziw M, Klimowicz AC, Petrillo SK, Craighead PS, Hao D, Diaz R, Lees-Miller SP, Magliocco AM (2010) Low ERCC1 and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone. Radiother Oncol 97:352–359PubMedCrossRef Doll CM, Prystajecky M, Eliasziw M, Klimowicz AC, Petrillo SK, Craighead PS, Hao D, Diaz R, Lees-Miller SP, Magliocco AM (2010) Low ERCC1 and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone. Radiother Oncol 97:352–359PubMedCrossRef
go back to reference Ferrigan L, Wallace WA (2004) Predicting non-small cell lung cancer expression of epidermal growth receptor and matrix metalloproteinase 9 from immunohistochemical staining of diagnostic biopsy samples. Eur J Cancer 40:1589–1592PubMedCrossRef Ferrigan L, Wallace WA (2004) Predicting non-small cell lung cancer expression of epidermal growth receptor and matrix metalloproteinase 9 from immunohistochemical staining of diagnostic biopsy samples. Eur J Cancer 40:1589–1592PubMedCrossRef
go back to reference Fountzilas G, Kalogera-Fountzila A, Lambaki S, Wirtz RM, Nikolau A, Karayannopoullou G, Bobos M, Kotoula V, Murray S, Lambropoulos A, Aravantinos G, Markou K, Athanassiou E, Misailidou D, Kalogeras KT, Skarlos D (2009) MMP9 but not EGFR, MET, ERCC1, P16 and P-53 is associated with response to concomitant radiotherapy, Cetuximab and weekly cisplatin in patients with locally advanced head and neck cancer. J Oncol. doi:10.1155/2009/305908 Fountzilas G, Kalogera-Fountzila A, Lambaki S, Wirtz RM, Nikolau A, Karayannopoullou G, Bobos M, Kotoula V, Murray S, Lambropoulos A, Aravantinos G, Markou K, Athanassiou E, Misailidou D, Kalogeras KT, Skarlos D (2009) MMP9 but not EGFR, MET, ERCC1, P16 and P-53 is associated with response to concomitant radiotherapy, Cetuximab and weekly cisplatin in patients with locally advanced head and neck cancer. J Oncol. doi:10.​1155/​2009/​305908
go back to reference Goyal S, Parikh RR (2010) Clinicopathologic significance of excision repair cross-complementation 1 expression in patients treated with breast-conserving surgery and radiation therapy. Int J Radiat Oncol Biol Phys 76:679–684PubMedCrossRef Goyal S, Parikh RR (2010) Clinicopathologic significance of excision repair cross-complementation 1 expression in patients treated with breast-conserving surgery and radiation therapy. Int J Radiat Oncol Biol Phys 76:679–684PubMedCrossRef
go back to reference Gregoire V, Lefebvre J-L, Licitra L, Felip E (2010) Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(suppl. 5):v184–v186PubMedCrossRef Gregoire V, Lefebvre J-L, Licitra L, Felip E (2010) Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(suppl. 5):v184–v186PubMedCrossRef
go back to reference Guo WF, Lin RX, Huang J, Zhou Z, Yang J, Guo GZ, Wang SQ (2005) Identification of differentially expressed genes contributing to radioresistance in lung cancer cells using microarray analysis. Radiat Res 164:27–35PubMedCrossRef Guo WF, Lin RX, Huang J, Zhou Z, Yang J, Guo GZ, Wang SQ (2005) Identification of differentially expressed genes contributing to radioresistance in lung cancer cells using microarray analysis. Radiat Res 164:27–35PubMedCrossRef
go back to reference Hayes M, Lan C, Yan J, Xie Y, Gray T, Amirkhan RH, Dowell JE (2011) ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation. Anticancer Res 31:4135–4139PubMed Hayes M, Lan C, Yan J, Xie Y, Gray T, Amirkhan RH, Dowell JE (2011) ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation. Anticancer Res 31:4135–4139PubMed
go back to reference Hwang IG, Ahn MJ, Park BB, Ahn YC, Han J, Lee S, Kim J, Shim YM, Ahn JS, Park K (2008) ERCC1 expression as a prognostic marker in N2 (+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer 113:1379–1386PubMedCrossRef Hwang IG, Ahn MJ, Park BB, Ahn YC, Han J, Lee S, Kim J, Shim YM, Ahn JS, Park K (2008) ERCC1 expression as a prognostic marker in N2 (+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer 113:1379–1386PubMedCrossRef
go back to reference Jeong J, Hong S-J, Ju Y-J, Kim B-Y, Park M-J, Kim T-H, Park C-I, Choi K-Y, Cho M-H, Kim S-H, Lee H, Lee K-H (2006) Temporal cDNa microarray analysis of gene expression in human hepatocellular carcinoma upon radiation exposure. Oncol Rep 15:33–48PubMed Jeong J, Hong S-J, Ju Y-J, Kim B-Y, Park M-J, Kim T-H, Park C-I, Choi K-Y, Cho M-H, Kim S-H, Lee H, Lee K-H (2006) Temporal cDNa microarray analysis of gene expression in human hepatocellular carcinoma upon radiation exposure. Oncol Rep 15:33–48PubMed
go back to reference Johung KL, Rewari A, Wu H, Contessa J, Haffty B, Decker R (2010) Role of excision repair cross complementation 1 expression as a prognostic marker for response to radiotherapy in early stage laryngeal cancer. Proceeding of the 52nd annual ASTRo meeting. Int J Radiat Oncol Biol Phys 78(Suppl):abstr. 3000 Johung KL, Rewari A, Wu H, Contessa J, Haffty B, Decker R (2010) Role of excision repair cross complementation 1 expression as a prognostic marker for response to radiotherapy in early stage laryngeal cancer. Proceeding of the 52nd annual ASTRo meeting. Int J Radiat Oncol Biol Phys 78(Suppl):abstr. 3000
go back to reference Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, Lee SK, Ahn YC, Jeong H-S, Son Y-I, Baek J-H, Park K (2008) ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer 99:167–172PubMedCrossRef Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, Lee SK, Ahn YC, Jeong H-S, Son Y-I, Baek J-H, Park K (2008) ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer 99:167–172PubMedCrossRef
go back to reference Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality and prevalence across five continents. Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137–2150PubMedCrossRef Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality and prevalence across five continents. Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137–2150PubMedCrossRef
go back to reference Kim MK, Cho K-J, Kwon GY, Park S-I, Kim YH, Kim JH, Song H-Y, Shin JH, Jung HY, Lee GH, Choi KD, Kim S-B (2008) Patients with ERCC1 negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. Clin Cancer Res 14:4225–4231PubMedCrossRef Kim MK, Cho K-J, Kwon GY, Park S-I, Kim YH, Kim JH, Song H-Y, Shin JH, Jung HY, Lee GH, Choi KD, Kim S-B (2008) Patients with ERCC1 negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. Clin Cancer Res 14:4225–4231PubMedCrossRef
go back to reference Kirschner K, Melton DW (2010) Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs. Anticancer Res 30:3223–3232PubMed Kirschner K, Melton DW (2010) Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs. Anticancer Res 30:3223–3232PubMed
go back to reference Lima LM, de Souza LR, da Silva TF, Pereira CS, Guimaraes AL, de Paula AM, de Carvalho Andrade H (2012) DNA repair gene excision repair cross complementing-group 1 (ERCC1) in head and neck squamous cell carcinoma: analysis of methylation and polymorphism (G19007A), protein expression and association with epidemiological and clinicopathological factors. Histopathology 60:489–496PubMedCrossRef Lima LM, de Souza LR, da Silva TF, Pereira CS, Guimaraes AL, de Paula AM, de Carvalho Andrade H (2012) DNA repair gene excision repair cross complementing-group 1 (ERCC1) in head and neck squamous cell carcinoma: analysis of methylation and polymorphism (G19007A), protein expression and association with epidemiological and clinicopathological factors. Histopathology 60:489–496PubMedCrossRef
go back to reference Mehra R, Cai KQ, Zhu F, Weaver J, Nicolaou N, Cohen RB, Lango M, Ridge JA, Godwin AK, Burtness B (2010) Analysis of ERCC1 (excision repair cross complementing group 1) in squamous cell carcinoma of the head and neck (SCCHN) by quantitative immunohistochemistry (IHC) using FL297. J Clin Oncol 28 (15s, Suppl):abstr. 5539 Mehra R, Cai KQ, Zhu F, Weaver J, Nicolaou N, Cohen RB, Lango M, Ridge JA, Godwin AK, Burtness B (2010) Analysis of ERCC1 (excision repair cross complementing group 1) in squamous cell carcinoma of the head and neck (SCCHN) by quantitative immunohistochemistry (IHC) using FL297. J Clin Oncol 28 (15s, Suppl):abstr. 5539
go back to reference Metzger R, Bollschweiler E, Hölscher AH, Warnecke-Eberz U (2010) ERCC1: impact in multimodality treatment of upper gastrointestinal cancer. Future Oncol 6:1735–1749PubMedCrossRef Metzger R, Bollschweiler E, Hölscher AH, Warnecke-Eberz U (2010) ERCC1: impact in multimodality treatment of upper gastrointestinal cancer. Future Oncol 6:1735–1749PubMedCrossRef
go back to reference Murray D, Rosenberg E (1996) The importance of the ERC1/ERCC4 [XPF] complex for hypoxic-cell radioresistance does not appear to derive from its participation in the nucleotide excision repair pathway. Mutat Res 364:217–226PubMedCrossRef Murray D, Rosenberg E (1996) The importance of the ERC1/ERCC4 [XPF] complex for hypoxic-cell radioresistance does not appear to derive from its participation in the nucleotide excision repair pathway. Mutat Res 364:217–226PubMedCrossRef
go back to reference Niedernhofer LJ, Odijk H, Budzowska M, van Drunen E, Maas A, Theil AF, de Wit J, Jaspers NGJ, Berna Beverloo H, Hoeijmakers JHJ, Kanaar R (2004) The structure-specific endonuclease ERCC1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 24:5776–5787PubMedCrossRef Niedernhofer LJ, Odijk H, Budzowska M, van Drunen E, Maas A, Theil AF, de Wit J, Jaspers NGJ, Berna Beverloo H, Hoeijmakers JHJ, Kanaar R (2004) The structure-specific endonuclease ERCC1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 24:5776–5787PubMedCrossRef
go back to reference Nix P, Greenman J, Cawkwell L (2004) Expression of XRCC1 and ERCC1 proteins in radioresistant and radiosensitive laryngeal cancer. Cancer Ther 2:47–53 Nix P, Greenman J, Cawkwell L (2004) Expression of XRCC1 and ERCC1 proteins in radioresistant and radiosensitive laryngeal cancer. Cancer Ther 2:47–53
go back to reference Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC (2006) DNA repair by ERCC1 in non-small cell lung cancer and cisplatin based adjuvant chemotherapy. N Engl J Med 355:983–991PubMedCrossRef Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC (2006) DNA repair by ERCC1 in non-small cell lung cancer and cisplatin based adjuvant chemotherapy. N Engl J Med 355:983–991PubMedCrossRef
go back to reference Reed E (1998) Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24:331–344PubMedCrossRef Reed E (1998) Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24:331–344PubMedCrossRef
go back to reference Romero Q, Bendahl P-O, Klintman M, Loman N, Ingvar C, Ryden L, Rose C, Grabau D, Borquist S (2011) Ki67 proliferation in core biopsies versus surgical samples—amodel for neo-adjuvant breast cancer studies. BMC Cancer. doi:10.1186/1471-2407-11-341 PubMed Romero Q, Bendahl P-O, Klintman M, Loman N, Ingvar C, Ryden L, Rose C, Grabau D, Borquist S (2011) Ki67 proliferation in core biopsies versus surgical samples—amodel for neo-adjuvant breast cancer studies. BMC Cancer. doi:10.​1186/​1471-2407-11-341 PubMed
go back to reference Sargent RG, Meservy JL, Perkins BD, Kilburn AE, Intody Z, Adair GM, Nairn RS, Wilson JH (2000) Role of the nucleotide excision repair gene ERCC1 in formation of recombination dependent rearrangements in mammalian cells. Nucleic Acids Res 28:3771–3778PubMedCrossRef Sargent RG, Meservy JL, Perkins BD, Kilburn AE, Intody Z, Adair GM, Nairn RS, Wilson JH (2000) Role of the nucleotide excision repair gene ERCC1 in formation of recombination dependent rearrangements in mammalian cells. Nucleic Acids Res 28:3771–3778PubMedCrossRef
go back to reference Scheil-Bertram S, Tylus-Schaaf P, du Bois A, Harter P, Oppitz M, Ewald-Riegler N, Fisseler-Eckhoff A (2010) Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high grade serous ovarian adenocarcinoma. Gynecol Oncol 119:325–331PubMedCrossRef Scheil-Bertram S, Tylus-Schaaf P, du Bois A, Harter P, Oppitz M, Ewald-Riegler N, Fisseler-Eckhoff A (2010) Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high grade serous ovarian adenocarcinoma. Gynecol Oncol 119:325–331PubMedCrossRef
go back to reference Shirota Y, Stoehlmacher J, Brabender J, Xiang YP, Uetake H, Danenberg KD, Groshens S, Tsao-Wei DD, Danenberg P, Lenz HJ (2001) ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19:4298–4304PubMed Shirota Y, Stoehlmacher J, Brabender J, Xiang YP, Uetake H, Danenberg KD, Groshens S, Tsao-Wei DD, Danenberg P, Lenz HJ (2001) ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19:4298–4304PubMed
go back to reference Simon GR, Sharma S, Cantor A, Smith P, Bepler G (2005) ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127:978–983PubMedCrossRef Simon GR, Sharma S, Cantor A, Smith P, Bepler G (2005) ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127:978–983PubMedCrossRef
go back to reference Taillade L, Penault-Llorca F, Boulet T, Fouret P, Michiels S, Taranchon E, Mountzios G, Validire P, Domont J, Girard P, Grunenwald D, Le Chevalier T, Soria J-C (2007) Immunohistochemical expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann Oncol 18:1043–1050PubMedCrossRef Taillade L, Penault-Llorca F, Boulet T, Fouret P, Michiels S, Taranchon E, Mountzios G, Validire P, Domont J, Girard P, Grunenwald D, Le Chevalier T, Soria J-C (2007) Immunohistochemical expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann Oncol 18:1043–1050PubMedCrossRef
go back to reference Zamble DB, Mu D, Reardon JT, Sancar A, Lippard SJ (1996) Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 35:10004–10013PubMedCrossRef Zamble DB, Mu D, Reardon JT, Sancar A, Lippard SJ (1996) Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 35:10004–10013PubMedCrossRef
Metadata
Title
Prognostic value of ERCC1 in head and neck carcinoma treated with definitive or adjuvant radiotherapy
Authors
Vesna Bišof
Antonija Jakovčević
Sven Seiwerth
Zoran Rakušić
Slavko Gašparov
Publication date
01-02-2013
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 2/2013
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-012-1318-8

Other articles of this Issue 2/2013

Journal of Cancer Research and Clinical Oncology 2/2013 Go to the issue